Glioblastoma (brain cancer) and LAT-1 program
Our brain cancer program targets two membrane transport proteins known as large amino acid transporter 1, and large amino acid transporter 2 (LAT1 and LAT2), validated targets that are highly expressed in several solid tumours, including malignancies of the central nervous system (CNS). We believe that the LAT1 and LAT2 receptors, which are expressed on both sides of the blood-brain barrier (BBB), are suitable targets for the delivery of radiation to both primary CNS malignancies and metastases from non-CNS cancers such as lung and breast cancer. As such, we see several potential indications for theranostic radiopharmaceuticals targeting LAT1 and LAT2.
Glioblastoma (GBM) – the most aggressive sub-type of glioma – has a poor prognosis, primarily due to there being few effective treatment options, with a median survival from initial diagnosis of 12-15 months. The mainstay of treatment for GBM is surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients.
With our TLX101 investigational therapy, we use a small molecule due to the need to cross the BBB, the normal protective barrier that prevents many potential drug candidates entering the brain.
Glioblastoma (GBM) worldwide
300,000
people were diagnosed with brain or central nervous system cancer globally in 2020
50%
of all brain tumours are GBM
12-15
months median overall survival from diagnosis
5%
5-year survival rate